Lung Cancer Diagnostics Market to Reach US$ 38 Billion by 2033 as Early Detection Demand Grows

Lung Cancer Diagnostics Market Size and Forecast 2025–2033

The global lung cancer diagnostics market is expected to witness substantial growth in the coming decade as healthcare systems increasingly focus on early cancer detection and precision medicine. According to Renub Research, the market is projected to grow from US$ 20.28 billion in 2024 to approximately US$ 38.00 billion by 2033, expanding at a compound annual growth rate (CAGR) of 7.23% from 2025 to 2033.

The increasing global burden of lung cancer, driven by smoking, air pollution, and lifestyle factors, is a key factor supporting market growth. Healthcare providers and governments are placing greater emphasis on early screening programs and advanced diagnostic technologies to improve survival rates.

Technological advancements in imaging, molecular diagnostics, and genomic testing have significantly enhanced the accuracy and speed of lung cancer detection. As a result, hospitals, diagnostic laboratories, and research institutions are investing heavily in innovative diagnostic tools that enable earlier and more precise diagnosis.

With increasing awareness of lung cancer risk factors and the benefits of early detection, the demand for diagnostic solutions is expected to grow steadily across global healthcare systems.

Lung Cancer Diagnostics Industry Overview

Lung cancer diagnostics involve a range of medical technologies and testing methods used to detect and evaluate lung cancer in patients. Early and accurate diagnosis is critical for determining the stage of cancer and selecting the most effective treatment strategy.

Common diagnostic methods include chest X-rays, computed tomography (CT) scans, magnetic resonance imaging (MRI), biopsies, and blood tests. These techniques help physicians identify abnormal lung tissue, detect tumors, and analyze genetic mutations associated with cancer.

In recent years, molecular and genomic diagnostic technologies have revolutionized cancer detection and treatment planning. These technologies allow doctors to analyze specific biomarkers and genetic mutations within tumors, enabling personalized treatment strategies.

The growing use of precision medicine is further accelerating demand for advanced diagnostic tools that can identify targeted therapy options for lung cancer patients.

Healthcare systems worldwide are also expanding public health programs aimed at increasing awareness and promoting regular cancer screenings among high-risk populations.

Key Drivers of the Lung Cancer Diagnostics Market

Rising Prevalence of Lung Cancer Worldwide

One of the primary drivers of the lung cancer diagnostics market is the increasing global incidence of lung cancer.

Smoking remains the leading cause of lung cancer, but environmental factors such as air pollution, occupational exposure to hazardous substances, and genetic predisposition also contribute significantly to the disease.

As lung cancer cases continue to rise worldwide, the demand for advanced diagnostic technologies capable of detecting cancer at earlier stages is growing rapidly.

Early detection significantly improves survival rates by enabling timely treatment interventions. As a result, healthcare providers are prioritizing screening programs and investing in advanced imaging and molecular diagnostic technologies.

Technological Advancements in Diagnostic Tools

Technological innovation has greatly improved the accuracy and efficiency of lung cancer diagnostics.

Advanced imaging technologies such as low-dose CT scans allow healthcare providers to detect lung tumors at early stages when treatment outcomes are more favorable.

In addition, molecular diagnostics and next-generation sequencing (NGS) technologies enable the identification of genetic mutations associated with lung cancer.

These innovations help doctors develop personalized treatment plans based on a patient’s specific genetic profile.

Artificial intelligence and machine learning technologies are also being integrated into diagnostic platforms to improve image analysis and reduce diagnostic errors.

The combination of advanced imaging, genomic analysis, and data-driven diagnostics is transforming lung cancer detection and treatment strategies.

Growing Awareness and Screening Programs

Public health initiatives aimed at increasing awareness about lung cancer are contributing to higher demand for diagnostic services.

Governments and healthcare organizations are launching awareness campaigns to educate populations about risk factors such as smoking, air pollution, and occupational hazards.

Screening programs targeting high-risk groups—such as long-term smokers—are also expanding worldwide.

These programs encourage early detection through regular imaging tests and diagnostic screenings, which improves survival outcomes and reduces healthcare costs associated with late-stage cancer treatment.

As awareness and healthcare accessibility improve, more individuals are seeking diagnostic services for early cancer detection.

Challenges in the Lung Cancer Diagnostics Market

High Cost of Advanced Diagnostic Technologies

Despite significant technological advancements, the high cost of advanced diagnostic equipment remains a challenge in many healthcare systems.

Sophisticated imaging systems, genomic testing platforms, and molecular diagnostic tools require substantial investment in equipment, infrastructure, and trained personnel.

These costs can limit access to advanced diagnostics, particularly in low- and middle-income countries.

Healthcare providers and governments are therefore exploring strategies to expand access to affordable diagnostic services through public-private partnerships and technology-sharing initiatives.

Regulatory and Data Management Challenges

The development and commercialization of new diagnostic technologies must comply with strict regulatory requirements.

Diagnostic products must undergo rigorous clinical validation to ensure accuracy, reliability, and patient safety.

Additionally, the growing use of genomic testing generates large volumes of sensitive patient data, raising concerns related to privacy, data security, and regulatory compliance.

Companies must implement strong data management frameworks and cybersecurity measures to ensure the protection of patient information.

Leading Companies in the Lung Cancer Diagnostics Market

Several global biotechnology and healthcare companies play a crucial role in advancing lung cancer diagnostic technologies.

Illumina Inc.

Illumina is a global leader in genomic sequencing technologies used in cancer research and molecular diagnostics. Its sequencing platforms and genomic analysis tools enable researchers and clinicians to identify genetic mutations associated with lung cancer.

The company’s products are widely used in pharmaceutical research, clinical laboratories, and academic institutions worldwide.

Abbott Laboratories

Abbott Laboratories develops a broad portfolio of diagnostic and healthcare solutions, including point-of-care testing systems and advanced laboratory technologies.

Its diagnostic platforms support early detection of diseases and help healthcare professionals make accurate treatment decisions.

Abbott’s global presence and extensive research capabilities strengthen its position in the lung cancer diagnostics market.

Thermo Fisher Scientific Inc.

Thermo Fisher Scientific is one of the world’s leading providers of life sciences and laboratory technologies.

The company offers a comprehensive range of diagnostic instruments, molecular biology tools, and laboratory services used in cancer research and clinical diagnostics.

Its solutions are widely used by pharmaceutical companies, hospitals, and research institutions.

QIAGEN N.V.

QIAGEN specializes in molecular diagnostic technologies that enable the analysis of DNA, RNA, and proteins from biological samples.

The company’s solutions support cancer diagnostics, infectious disease detection, and genomic research.

QIAGEN’s automated testing systems and bioinformatics platforms are widely used in clinical laboratories worldwide.

Roche Holding AG

Roche is a global biotechnology company known for its leadership in oncology diagnostics and precision medicine.

The company develops in-vitro diagnostic systems and tissue-based cancer diagnostics that enable healthcare providers to identify cancer biomarkers and genetic mutations.

Roche’s strong focus on research and development has positioned it as a key player in the global cancer diagnostics market.

Recent Developments in the Lung Cancer Diagnostics Market

The lung cancer diagnostics industry continues to evolve through technological innovation and global healthcare collaborations.

In March 2025, Agilent Technologies announced that its PD-L1 IHC 28-8 pharmDx diagnostic kit received new approvals under the EU In Vitro Diagnostic Regulation (IVDR), expanding its use for early-stage lung cancer and advanced melanoma diagnosis.

In July 2024, Danaher Corporation opened two new CLIA and CAP-certified laboratories to accelerate the development of companion diagnostics and complementary diagnostics for targeted cancer therapies.

Another important development involves a partnership between Siemens Healthineers and the International Atomic Energy Agency (IAEA) to improve cancer diagnosis and treatment capabilities in low- and middle-income countries.

This collaboration supports the Rays of Hope initiative, which aims to expand access to cancer care and reduce global mortality rates associated with non-communicable diseases.

Sustainability and Innovation in Diagnostics

Healthcare companies are increasingly integrating sustainability principles into their diagnostic operations.

For example, Guardant Health focuses on improving cancer detection through precision oncology while maintaining environmentally responsible laboratory operations.

Similarly, Veracyte Inc. emphasizes sustainable innovation by developing genomic diagnostics that improve healthcare efficiency and reduce unnecessary medical procedures.

These initiatives demonstrate how healthcare organizations are combining technological advancement with environmental and social responsibility.

Market Segmentation

The lung cancer diagnostics market includes several diagnostic technologies and services used across healthcare settings.

By Technology

• Imaging Tests

• Biopsy

• Molecular Diagnostics

• Blood Tests

By End User

• Hospitals

• Diagnostic Laboratories

• Research Institutes

• Cancer Centers

Final Thoughts

The lung cancer diagnostics market is expected to experience strong growth in the coming years as global healthcare systems prioritize early cancer detection and precision medicine.

With the market projected to reach US$ 38 billion by 2033, advancements in imaging technology, genomic testing, and molecular diagnostics will continue to transform the way lung cancer is detected and treated.

Increasing public awareness, expanding screening programs, and growing investments in healthcare infrastructure will further support market expansion.

Although challenges such as high costs and regulatory complexities remain, ongoing innovation and collaboration across the healthcare sector ensure a promising future for lung cancer diagnostics worldwide.